Table 1. Description of enrolled GBS patients.
| Basic information | |
|---|---|
| Male/female ratio | 108/78 |
| Age (years) a | 40.5 (29.75-54.25) |
| Duration in hospital (days)a | 14 (9-19) |
| Medical history | |
| Hypertension | 17.20% |
| Diabetes | 4.84% |
| Symptoms of antecedent infection | 57.52% |
| Interval between infection and onset (days)a | 5 (2-12) |
| Diarrhea | 31.72% |
| Upper respiratory tract infection | 29.03% |
| Clinical manifestations | |
| MRC sum score at admission a | 42 (35.5-52.5) |
| GBS disability scale score at admission a | 4 (2-4) |
| MRC sum score at nadira | 40 (30.75-48) |
| GBS disability scale score at nadir a | 4 (3-4) |
| Interval between onset and nadir (days) a | 6 (4-8) |
| MRC sum score at discharge a | 52 (44-60) |
| GBS disability scale score at dischargea | 2 (1-4) |
| Decreased muscle tonus | 26.88% |
| Cranial nerve involvement | 45.16% |
| Hyporeflexia/areflexia | 85.55% |
| Superficial sensation deficits | 45.70% |
| Deep sensation deficits | 5.91% |
| Autonomic deficits | 57.53% |
| Dyspnea | 26.34% |
| Ventilator dependence | 15.05% |
| Complications during hospitalization | |
| Pulmonary infection | 20.43% |
| Embolism | 2.15% |
| Electrolyte disturbance | 5.91% |
| Blood routine examination at admission | |
| White blood cell (*109/L)b | 9.14 |
| Neutrophil (%)b | 0.69 |
| Lymphocyte (%)b | 0.24 |
| Lumbar puncture | |
| Protein concentration (g/L)b | 0.64 |
| White blood cell (106/L)a | 4 (2-7) |
| Albumin-cytologic dissociations | 62.61% |
| IgG concentration (mg/L)b | 100.33 |
| Nerve conduction studies | |
| Demyelinating group | 49.09% |
| Axonal group | 30.90% |
| Overlap group | 20.01% |
| Treatment | |
| IVIg | 40.32% |
| Interval between onset and IVIga | 4 (3-7) |
| Glucocorticoids | 13.44% |
| IVIg + Glucocorticoids | 20.43% |
| Supportive care | 25.81% |
aMedian (IQR)
bAverage